In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.
A new macrolide (A-56268) was found to be approximately twice as active as erythromycin and four to eight times more active than roxithromycin. All three macrolides were similar in their potency against anaerobes. Human plasma enhanced the antistaphylococcal activity of A-56268 and erythromycin but reduced the activities of roxithromycin and clindamycin.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001421:Bacteria, Anaerobic / Q000187:drug effects; D017291:Clarithromycin; D002981:Clindamycin / Q000494:pharmacology; D003470:Culture Media; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D007933:Leucomycins / Q000494:pharmacology; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D003470:Culture Media; D007933:Leucomycins; D002981:Clindamycin; D004917:Erythromycin; D017291:Clarithromycin